Drug profile · INN
vorinostat
ZOLINZA
vorinostat (ZOLINZA) is a histone deacetylase 3 inhibitor. Associated with Merck KGaA, Darmstadt, Germany. Route of administration: oral. Current US regulatory status: approved.
Drug details — vorinostat
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
vorinostat (ZOLINZA) is a histone deacetylase 3 inhibitor. Associated with Merck KGaA, Darmstadt, Germany. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Histone deacetylase 3 inhibitor
Primary target: Histone deacetylase 1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | application withdrawn | — |
| TGA | approved | — |
Frequently asked questions
What is vorinostat?
vorinostat (ZOLINZA) is a histone deacetylase 3 inhibitor. Associated with Merck KGaA, Darmstadt, Germany. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for vorinostat?
ZOLINZA is a marketed brand name for vorinostat. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of vorinostat?
vorinostat has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.